Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $205
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $205.
Canaccord Genuity analyst Kyle Mikson maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $135 to $205.